Literature DB >> 16682968

Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers.

Dymphy R H Huntjens1, David J M Spalding, Meindert Danhof, Oscar E Della Pasqua.   

Abstract

Understanding the mechanisms underlying the analgesic effect of new cyclooxygenase inhibitors is essential to identify dosing requirements in early stages of drug development. Accurate extrapolation to humans of in vitro and in vivo findings in preclinical species is needed to optimise dosing regimen in inflammatory conditions. The current investigation characterises the inhibition of prostaglandin E2 (PGE(2)) and thromboxane B2 (TXB(2)) by naproxen in vitro and in vivo in rat and human blood. The inhibition of PGE(2) in the absence or presence of increasing concentrations of naproxen (10(-8)-10(-1) M) was measured by ex vivo whole blood stimulation with LPS, whereas inhibition of TXB(2) was measured in serum following blood clotting. In further experiments, inhibition of PGE(2) and TXB(2) levels was also assessed ex vivo in animals treated with naproxen (2.5, 10, 25 mg kg(-1)). Subsequently, pharmacokinetic (PK)/pharmacodynamics (PD) modelling of in vitro and in vivo data was performed using nonlinear mixed effects in NONMEM (V). Inhibition of PGE(2) and TXB(2) was characterised by a sigmoid E(max) model. The exposure-response relationships in vitro and in vivo were of the same order of magnitude in both species. IC(80) estimates obtained in vitro were similar for PGE(2) inhibition (130.8 +/- 11 and 131.9 +/- 19 10(-6) M, mean +/- s.d. for humans and rats, respectively), but slightly different for TXB(2) inhibition (103.9+/-15 and 151.4 +/- 40 10(-6) M, mean +/- s.d. for humans and rats, respectively, P < 0.05). These differences, however, may not be biologically relevant. The results confirm the value of exposure-effect relationships determined in vitro as a means to predict the pharmacological activity in vivo. This analysis also highlights the need to parameterise concentration-effect relationships in early drug development, as indicated by the estimates of IC(80) for PGE(2) and TXB(2) inhibition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16682968      PMCID: PMC1751780          DOI: 10.1038/sj.bjp.0706737

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  26 in total

Review 1.  Pharmacokinetic/pharmacodynamic modeling in drug research and development.

Authors:  H Derendorf; L J Lesko; P Chaikin; W A Colburn; P Lee; R Miller; R Powell; G Rhodes; D Stanski; J Venitz
Journal:  J Clin Pharmacol       Date:  2000-12       Impact factor: 3.126

2.  Involvement of peripheral cyclooxygenase-1 and cyclooxygenase-2 in inflammatory pain.

Authors:  Rosa Ventura Martínez; MaIreneDíaz Reval; Myrna Déciga Campos; José Antonio Terrón; RamírezAdrianaM Domínguez; Francisco J López-Muñoz
Journal:  J Pharm Pharmacol       Date:  2002-03       Impact factor: 3.765

3.  High-performance liquid chromatographic determination of ketoprofen and naproxen in rat plasma.

Authors:  J H Satterwhite; F D Boudinot
Journal:  J Chromatogr       Date:  1988-10-14

4.  Kinetic basis for selective inhibition of cyclo-oxygenases.

Authors:  J K Gierse; C M Koboldt; M C Walker; K Seibert; P C Isakson
Journal:  Biochem J       Date:  1999-05-01       Impact factor: 3.857

5.  Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.

Authors:  Karine M Egan; Miao Wang; Susanne Fries; Margaret B Lucitt; Alicia M Zukas; Ellen Puré; John A Lawson; Garret A FitzGerald
Journal:  Circulation       Date:  2005-01-17       Impact factor: 29.690

6.  Pharmacokinetic/pharmacodynamic modeling of antipyretic and anti-inflammatory effects of naproxen in the rat.

Authors:  M Josa; J P Urizar; J Rapado; C Dios-Viéitez; G Castañeda-Hernández; F Flores-Murrieta; M J Renedo; I F Trocóniz
Journal:  J Pharmacol Exp Ther       Date:  2001-04       Impact factor: 4.030

Review 7.  New insights into COX-2 biology and inhibition.

Authors:  Paola Patrignani; Stefania Tacconelli; Maria Gina Sciulli; Marta L Capone
Journal:  Brain Res Brain Res Rev       Date:  2005-04

8.  Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis.

Authors:  T D Warner; F Giuliano; I Vojnovic; A Bukasa; J A Mitchell; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

9.  Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects.

Authors:  M Hassan-Alin; J Naesdal; C Nilsson-Pieschl; G Långström; T Andersson
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

10.  Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings.

Authors:  M R Panara; R Padovano; M G Sciulli; G Santini; G Renda; M T Rotondo; A Pace; C Patrono; P Patrignani
Journal:  Clin Pharmacol Ther       Date:  1998-06       Impact factor: 6.875

View more
  13 in total

1.  Model-based prediction of the acute and long-term safety profile of naproxen in rats.

Authors:  Tarjinder Sahota; Ian Sanderson; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Pharmacol       Date:  2015-06-29       Impact factor: 8.739

2.  Pharmacokinetic-pharmacodynamic modeling of the inhibitory effects of naproxen on the time-courses of inflammatory pain, fever, and the ex vivo synthesis of TXB2 and PGE2 in rats.

Authors:  Elke H J Krekels; Marie Angesjö; Ingemo Sjögren; Kristina Angeby Möller; Odd-Geir Berge; Sandra A G Visser
Journal:  Pharm Res       Date:  2011-02-23       Impact factor: 4.200

3.  Effect of Disease-Related Changes in Plasma Albumin on the Pharmacokinetics of Naproxen in Male and Female Arthritic Rats.

Authors:  Xiaonan Li; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Drug Metab Dispos       Date:  2017-02-28       Impact factor: 3.922

4.  Modeling Sex Differences in Pharmacokinetics, Pharmacodynamics, and Disease Progression Effects of Naproxen in Rats with Collagen-Induced Arthritis.

Authors:  Xiaonan Li; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Drug Metab Dispos       Date:  2017-02-28       Impact factor: 3.922

5.  Ondansetron blocks wild-type and p.F503L variant small-conductance Ca2+-activated K+ channels.

Authors:  Jum-Suk Ko; Shuai Guo; Jonathan Hassel; Patricia Celestino-Soper; Ty C Lynnes; James E Tisdale; James J Zheng; Stanley E Taylor; Tatiana Foroud; Michael D Murray; Richard J Kovacs; Xiaochun Li; Shien-Fong Lin; Zhenhui Chen; Matteo Vatta; Peng-Sheng Chen; Michael Rubart
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-04-20       Impact factor: 4.733

6.  Pharmacokinetic-pharmacodynamic modeling of diclofenac in normal and Freund's complete adjuvant-induced arthritic rats.

Authors:  Jing Zhang; Pei Li; Hai-fang Guo; Li Liu; Xiao-dong Liu
Journal:  Acta Pharmacol Sin       Date:  2012-07-30       Impact factor: 6.150

Review 7.  Use of sensory methods for detecting target engagement in clinical trials of new analgesics.

Authors:  Boris A Chizh; Christine N Sang
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

8.  Development, Internal and External Validation of Naproxen Sodium Sustained Release Formulation: an Level A In Vitro-In Vivo Correlation.

Authors:  Ramesh Narayanasamy; Ramakrishna Shabaraya
Journal:  Turk J Pharm Sci       Date:  2017-08-15

9.  The impact of composite AUC estimates on the prediction of systemic exposure in toxicology experiments.

Authors:  Tarjinder Sahota; Meindert Danhof; Oscar Della Pasqua
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-04-14       Impact factor: 2.745

10.  Novel Activities of Select NSAID R-Enantiomers against Rac1 and Cdc42 GTPases.

Authors:  Tudor I Oprea; Larry A Sklar; Jacob O Agola; Yuna Guo; Melina Silberberg; Joshua Roxby; Anna Vestling; Elsa Romero; Zurab Surviladze; Cristina Murray-Krezan; Anna Waller; Oleg Ursu; Laurie G Hudson; Angela Wandinger-Ness
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.